Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Economic Evaluation of Once-Weekly Insulin Icodec from Italian NHS Perspective

Title: Economic Evaluation of Once-Weekly Insulin Icodec from Italian NHS Perspective
Authors: Torre,Enrico; Di Matteo,Sergio; Bruno,Giacomo; Martinotti,Chiara; Bottaro,Luigi; Colombo,Giorgio
Publisher Information: Dove Press
Publication Year: 2024
Collection: Dove Medical Press
Subject Terms: ClinicoEconomics and Outcomes Research
Description: Enrico Torre,1 Sergio Di Matteo,2 Giacomo Matteo Bruno,3 Chiara Martinotti,2 Luigi Carlo Bottaro,4 Giorgio Lorenzo Colombo3 1Diabetology and Metabolic Diseases Unit - ASL3, Genoa, Italy; 2Center of Research, SAVE Studi - Health Economics and Outcomes Research, Milan, Italy; 3Department of Drug Sciences, University of Pavia, Pavia, Italy; 4General Direction, ASL3 –, Genoa, ItalyCorrespondence: Giorgio Lorenzo Colombo, Email giorgio.colombo@unipv.itBackground: Icodec, once-weekly basal insulin, aims to simplify therapy management by reducing injection frequency for diabetic patients. The efficacy and safety of icodec were evaluated in the ONWARDS clinical development program. This study evaluates icodec economic and quality of life impact from the Italian National Healthcare System (NHS) perspective.Materials and Methods: A pharmacoeconomic study was developed to assess the once-weekly insulin icodec value, highlighting its potential to decrease needle use while improving adherence and quality of life. In the base case, a differential cost and cost-utility analysis over one year compared to once-daily insulin degludec were developed. Based on the comparison with degludec, a scenario analysis was planned between icodec and the mix of basal insulins available on the market. Economic evaluations included drug and administration costs, needles, and impact on adherence. The cost-utility analysis measured the utility associated with the weekly injection compared to the daily ones, resulting in an incremental cost-effectiveness ratio (ICER), measured as Δ€/ΔQALY (Quality Adjusted Life Years). To assess the robustness of the results, a deterministic one-way sensitivity analysis and a probabilistic sensitivity analysis were carried out.Results: At an annual cost 25% higher than degludec, considering the economic benefits generated by the needle use reduction (-€ 51.10) and adherence improvement (-€ 54.85), once-weekly icodec grants no incremental cost and even potential savings per patient. Furthermore, icodec ...
Document Type: article in journal/newspaper
File Description: text/html
Language: English
Availability: https://www.dovepress.com/economic-evaluation-of-once-weekly-insulin-icodec-from-italian-nhs-per-peer-reviewed-fulltext-article-CEOR
Rights: info:eu-repo/semantics/openAccess
Accession Number: edsbas.EDF570CF
Database: BASE